Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.

PMID:
30419344
2.

Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium.

Van Valckenborgh E, Hébrant A, Antoniou A, Van Hoof W, Van Bussel J, Pauwels P, Salgado R, Van Doren W, Waeytens A, Van den Bulcke M.

Arch Public Health. 2018 Sep 6;76:49. doi: 10.1186/s13690-018-0295-z. eCollection 2018.

3.

Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.

Vermaelen K, Waeytens A, Kholmanskikh O, Van den Bulcke M, Van Valckenborgh E.

Semin Cancer Biol. 2018 Oct;52(Pt 2):166-177. doi: 10.1016/j.semcancer.2017.11.011. Epub 2017 Nov 21. Review.

PMID:
29170067
4.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

5.

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K.

J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30.

PMID:
27976373
6.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

7.

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.

Binsfeld M, Muller J, Lamour V, De Veirman K, De Raeve H, Bellahcène A, Van Valckenborgh E, Baron F, Beguin Y, Caers J, Heusschen R.

Oncotarget. 2016 Jun 21;7(25):37931-37943. doi: 10.18632/oncotarget.9270.

8.

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.

Oncotarget. 2016 Jun 21;7(25):38927-38945. doi: 10.18632/oncotarget.7792. Review.

9.

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K, De Bruyne E.

Oncotarget. 2016 Jul 26;7(30):48732-48752. doi: 10.18632/oncotarget.8982. Review.

10.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I.

Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19.

PMID:
27102001
11.

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.

Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K.

Oncotarget. 2016 Jul 5;7(27):42698-42715. doi: 10.18632/oncotarget.8311. Review.

12.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.

13.

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Review.

14.

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI.

Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983.

15.

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E.

Oncotarget. 2015 Dec 22;6(41):43992-4004. doi: 10.18632/oncotarget.6083.

16.

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Fristedt Duvefelt C, Lub S, Agarwal P, Arngården L, Hammarberg A, Maes K, Van Valckenborgh E, Vanderkerken K, Jernberg Wiklund H.

Oncotarget. 2015 Aug 21;6(24):20621-35.

17.

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.

De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2015 Apr 30;6(12):10532-47.

18.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.

19.

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA.

Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Review.

20.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E.

Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21.

PMID:
25142285
21.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 Nov 30;5(22):11193-208.

22.

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K.

Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363.

23.

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E.

Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.

24.

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 May 30;5(10):3115-29.

25.

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E.

Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.

26.

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Lemaire M, D'Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K.

Leukemia. 2014 Feb;28(2):444-7. doi: 10.1038/leu.2013.292. Epub 2013 Oct 9. No abstract available.

PMID:
24166214
27.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

28.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E.

PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013.

29.

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K.

Dis Model Mech. 2012 Nov;5(6):763-71. doi: 10.1242/dmm.008961. Review.

30.

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E.

Biochem Biophys Res Commun. 2012 Nov 30;428(4):518-24. doi: 10.1016/j.bbrc.2012.10.071. Epub 2012 Oct 27.

PMID:
23111325
31.

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.

Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P, Vanderkerken K, Van Ginderachter JA.

Leukemia. 2012 Nov;26(11):2424-8. doi: 10.1038/leu.2012.113. Epub 2012 Apr 23. No abstract available.

PMID:
22522789
32.

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Österborg A, Atadja P, Larsson O, Axelson M, Van Camp B, Jernberg-Wiklund H, Vanderkerken K.

Clin Cancer Res. 2012 Apr 15;18(8):2230-9. doi: 10.1158/1078-0432.CCR-11-1764. Epub 2012 Mar 5.

33.

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model.

Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Dehui X, De Bruyne E, Menu E, Empsen C, van Grunsven L, Agarwal J, Wang Q, Jernberg-Wiklund H, Vanderkerken K.

Leukemia. 2012 Jun;26(6):1436-9. doi: 10.1038/leu.2011.373. Epub 2012 Jan 6. No abstract available.

34.

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.

Blood. 2012 Jan 19;119(3):826-37. doi: 10.1182/blood-2011-07-366492. Epub 2011 Nov 29. Erratum in: Blood. 2014 Jul 24;124(4):663. De Bryune, Elke [corrected to De Bruyne, Elke].

35.

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E.

Leukemia. 2012 Jun;26(6):1402-5. doi: 10.1038/leu.2011.332. Epub 2011 Nov 18. No abstract available.

PMID:
22094583
36.

The microenvironment and molecular biology of the multiple myeloma tumor.

Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K.

Adv Cancer Res. 2011;110:19-42. doi: 10.1016/B978-0-12-386469-7.00002-5. Review.

PMID:
21704227
37.

The effects of forodesine in murine and human multiple myeloma cells.

Bieghs L, Caers J, De Bruyne E, Van Valckenborgh E, Higginbotham F, Vanderkerken K, Menu E.

Adv Hematol. 2010;2010:131895. doi: 10.1155/2010/131895. Epub 2010 Oct 19.

38.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

39.

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K.

Blood. 2010 Mar 25;115(12):2430-40. doi: 10.1182/blood-2009-07-232801. Epub 2010 Jan 19.

40.

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Caers J, Hose D, Kuipers I, Bos TJ, Van Valckenborgh E, Menu E, De Bruyne E, Goldschmidt H, Van Camp B, Klein B, Vanderkerken K.

Haematologica. 2010 Jan;95(1):163-7. doi: 10.3324/haematol.2009.006411. Epub 2009 Oct 14.

41.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

42.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.

Leukemia. 2009 Oct;23(10):1894-903. doi: 10.1038/leu.2009.121. Epub 2009 Jun 4.

PMID:
19494837
43.

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.

Menu E, van Valckenborgh E, van Camp B, Vanderkerken K.

Arch Physiol Biochem. 2009 May;115(2):49-57. doi: 10.1080/13813450902736583. Review.

PMID:
19234898
44.

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K.

Br J Cancer. 2008 Jun 17;98(12):1966-74. doi: 10.1038/sj.bjc.6604388. Epub 2008 Jun 3.

45.

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.

Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489.

46.

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.

Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K.

Bull Cancer. 2008 Mar;95(3):301-13. doi: 10.1684/bdc.2008.0600. Review.

47.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network.

Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11.

48.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

49.

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K.

Leukemia. 2007 Jul;21(7):1580-4. Epub 2007 Mar 22. No abstract available.

50.

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.

Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3.

PMID:
17086356

Supplemental Content

Loading ...
Support Center